FDA Recommends Against Using Certain Test on Ranitidine, Says it May Generate NDMA in Sample

Date : 10/02/2019 @ 9:26PM
Source : Dow Jones News
Stock : Kroger Co (KR)
Quote : 29.65  0.52 (1.79%) @ 12:40AM
Kroger share price Chart
After Hours
Last Trade
Last $ 29.65 ◊ 0.00 (0.00%)

FDA Recommends Against Using Certain Test on Ranitidine, Says it May Generate NDMA in Sample

Walmart (NYSE:WMT)
Historical Stock Chart

6 Months : From Sep 2019 to Mar 2020

Click Here for more Walmart Charts.
   By Stephen Nakrosis 

The U.S. Food and Drug Administration on Wednesday said a method of testing the drug ranitidine for impurities is not suitable to detect the presence of NDMA, a possible carcinogenic, because the testing method may generate NDMA.

According to the agency, a testing method employing high temperatures "generated very high levels of NDMA from ranitidine products because of the test procedure." That method was used by a third-party laboratory, whose work was observed by the FDA.

The FDA said a liquid chromatography-high resolution mass spectrometry, or LC-HRMS, method should be used to test for the presence of NDMA. "FDA's LC-HRMS testing method does not use elevated temperatures and has shown the presence of much lower levels of NDMA in ranitidine medicines than reported by the third-party laboratory."

The agency said it is continuing tests of ranitidine products from a number of manufacturers, and is asking ranitidine manufacturers to send samples of their products to the agency for testing by FDA scientists.

Ranitidine is used to treat heartburn and other gastrointestinal disorders.

The FDA last month said it detected low levels of NDMA, a probable carcinogenic, in the heartburn treatment Zantac. Ranitidine is an active ingredient in Zantac.

Since then, a number of retailers, including Walmart Inc. (WMT), Walgreens (WBA) and Kroger Co. (KR) have removed treatments containing ranitidine from their shelves.

In a release last month, the FDA notified professionals and patients about the voluntary recall, but said not all ranitidine medicines are being recalled, and added it wasn't recommending individuals stop taking all ranitidine medicines.


--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com


(END) Dow Jones Newswires

October 02, 2019 16:11 ET (20:11 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest KR Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:us D:20200331 02:52:00